Canadian Consensus Conference on Osteoporosis, 2006 Update

被引：55

作者：

Brown, Jacques P.

Fortier, Michel

Frame, Heather

Lalonde, Andre

Papaioannou, Alexandra

Senikas, Vyta

Yuen, Chui Kin

Henneberg, Elke

Oman, Jackie

机构：

[1] Quebec, QC

[2] Winnipeg, MB

[3] Ottawa, ON

[4] Hamilton, ON

[5] Communications Message and More Inc., Sutton, QC

来源：

JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA | 2006年 / 28卷 / 02期

关键词：

Osteoporosis; prevention; treatment; diagnosis; bone mineral density; dual energy X-ray absorptiometry; bone turnover markers; vertebral fractures; fragility fractures; antiresorptive; hormone therapy; selective estrogen receptor modulator; bisphosphonates; calcitonin; anabolic; bone forming agent;

D O I：

10.1016/S1701-2163(16)32087-4

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: To provide guidelines for the health care provider on the diagnosis and clinical management of postmenopausal osteoporosis. Outcomes: Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and bone turnover markers in assessing diagnosis and response to management, and recommendations regarding nutrition, physical activity, and the selection of pharmacologic therapy to prevent and manage osteoporosis. Evidence: MEDLINE and the Cochrane database were searched for articles in English on subjects related to osteoporosis diagnosis, prevention, and management from March 2001 to April 2005. The authors critically reviewed the evidence and developed the recommendations according to the Journal of Obstetrics and Gynaecology Canada's methodology and consensus development process. Values: The quality of evidence is rated using the criteria described in the report of the Canadian Task Force on the Periodic Health Examination. Recommendations for practice are ranked according to the method described in this report.

引用

页码：S95 / S112

页数：18

共 134 条

[1]

[Anonymous], 2000, NIH Consens Statement, V17, P1

[2] Raloxifene and cardiovascular events in osteoporotic postmenopausal women - Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial [J].